Your browser doesn't support javascript.
loading
Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19.
Kartsonaki, Christiana; Baillie, J Kenneth; Barrio, Noelia García; Baruch, Joaquín; Beane, Abigail; Blumberg, Lucille; Bozza, Fernando; Broadley, Tessa; Burrell, Aidan; Carson, Gail; Citarella, Barbara Wanjiru; Dagens, Andrew; Dankwa, Emmanuelle A; Donnelly, Christl A; Dunning, Jake; Elotmani, Loubna; Escher, Martina; Farshait, Nataly; Goffard, Jean-Christophe; Gonçalves, Bronner P; Hall, Matthew; Hashmi, Madiha; Sim Lim Heng, Benedict; Ho, Antonia; Jassat, Waasila; Pedrera Jiménez, Miguel; Laouenan, Cedric; Lissauer, Samantha; Martin-Loeches, Ignacio; Mentré, France; Merson, Laura; Morton, Ben; Munblit, Daniel; Nekliudov, Nikita A; Nichol, Alistair D; Singh Oinam, Budha Charan; Ong, David; Panda, Prasan Kumar; Petrovic, Michele; Pritchard, Mark G; Ramakrishnan, Nagarajan; Ramos, Grazielle Viana; Roger, Claire; Sandulescu, Oana; Semple, Malcolm G; Sharma, Pratima; Sigfrid, Louise; Somers, Emily C; Streinu-Cercel, Anca; Taccone, Fabio.
Afiliação
  • Kartsonaki C; Medical Research Council (MRC) Population Health Research Unit, Clinical Trials Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Baillie JK; Roslin Institute, University of Edinburgh, Edinburgh, UK.
  • Barrio NG; Intensive Care Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.
  • Baruch J; Hospital 12 de Octubre, Madrid, Spain.
  • Beane A; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Blumberg L; Critical Care Asia, Bangkok, Thailand.
  • Bozza F; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Broadley T; National Institute of Infectious Disease Evandro Chagas, Oswaldo Cruz Foundation (INI-FIOCRUZ), Ministry of Health, and D'Or Institute of Research and Education (IDOR), Rio de Janeiro, São Paulo, Brazil.
  • Burrell A; Monash University, Clayton, Melbourne, Australia.
  • Carson G; Monash University, Clayton, Melbourne, Australia.
  • Citarella BW; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Dagens A; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Dankwa EA; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Donnelly CA; Department of Statistics, University of Oxford, Oxford, UK.
  • Dunning J; Department of Statistics, University of Oxford, Oxford, UK.
  • Elotmani L; MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics and Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
  • Escher M; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Farshait N; CHU Caremeau, Nîmes, France.
  • Goffard JC; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Gonçalves BP; Humber River Hospital, Toronto, Canada.
  • Hall M; Cliniques Universitaires de Bruxelles (CUB) Hopital Erasme, Anderlecht, Belgium.
  • Hashmi M; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Sim Lim Heng B; Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Ho A; Critical Care Asia and Ziauddin University, Karachi, Pakistan.
  • Jassat W; Hospital Sungai Buloh, Ministry of Health, Sungai Buloh, Malaysia.
  • Pedrera Jiménez M; Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow, UK Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, UK.
  • Laouenan C; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Lissauer S; Hospital 12 de Octubre, Madrid, Spain.
  • Martin-Loeches I; Un iversité de Paris, France, Infection, Antimicrobials, Modelling, Evolution (IAME), INSERM, Paris, France.
  • Mentré F; Malawi-Liverpool Wellcome Trust, Blantyre, Malawi.
  • Merson L; St James's Hospital, Dublin, Ireland.
  • Morton B; Un iversité de Paris, France, Infection, Antimicrobials, Modelling, Evolution (IAME), INSERM, Paris, France.
  • Munblit D; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Nekliudov NA; Infectious Diseases Data Observatory, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
  • Nichol AD; Liverpool School of Tropical Medicine, Liverpool, UK.
  • Singh Oinam BC; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Ong D; Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK.
  • Panda PK; Sechenov University, Moscow, Russia.
  • Petrovic M; Irish Critical Care Critical Clinical Trials Network, Dublin, Ireland.
  • Pritchard MG; All India Institute of Medical Sciences (AIIMS), Rishikesh, India.
  • Ramakrishnan N; Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands.
  • Ramos GV; All India Institute of Medical Sciences (AIIMS), Rishikesh, India.
  • Roger C; Humber River Hospital, Toronto, Canada.
  • Sandulescu O; International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Global Support Centre, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Semple MG; Apollo Hospitals Chennai, Chennai, India.
  • Sharma P; National Institute of Infectious Disease Evandro Chagas, Oswaldo Cruz Foundation (INI-FIOCRUZ), Ministry of Health, and D'Or Institute of Research and Education (IDOR), Rio de Janeiro, São Paulo, Brazil.
  • Sigfrid L; CHU Caremeau, Nîmes, France.
  • Somers EC; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Streinu-Cercel A; National Institute for Infectious Diseases 'Prof. Dr. Matei Bals', Bucharest, Romania.
  • Taccone F; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
Int J Epidemiol ; 52(2): 355-376, 2023 04 19.
Article em En | MEDLINE | ID: mdl-36850054
BACKGROUND: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. METHODS: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV). RESULTS: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%. CONCLUSIONS: Age was the strongest determinant of risk of death, with a ∼30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans / Male / Middle aged Idioma: En Revista: Int J Epidemiol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans / Male / Middle aged Idioma: En Revista: Int J Epidemiol Ano de publicação: 2023 Tipo de documento: Article